Scholarlink

Purpose <p>We aimed to conduct a retrospective analysis to assess the efficacy and safety of finerenone in patients with membranous nephropathy (MN).</p> Methods <p>This study conducted a retrospective analysis of patients with MN who were treated with finerenone for follow-up period ranging from 3 to 6&#xa0;months. The study compared the estimated glomerular filtration rate (eGFR), urine total protein-to-creatinine ratio (PCR), urine albumin-to-creatinine ratio (ACR), serum creatinine concentration (SCr), blood pressure and serum potassium (K+) during the follow-up period.</p> Result <p>In this study, 20 patients with MN were treated with finerenone for a follow-up period of 3 to 6&#xa0;months. Prior to treatment, the average eGFR was 65.15&#xa0;mL/min/1.73&#xa0;m<sup>2</sup>, the average PCR was 3643.63&#xa0;mg/g, and the average ACR was 2489.44&#xa0;mg/g. After 3&#xa0;months of treatment, 80% of patients experienced a decrease in PCR. The median decrease percentages in PCR and ACR are 24.49% and 28.82%, respectively. After 6&#xa0;months of treatment, the median decrease percentages in PCR and ACR are 42.03% and 43.66%, respectively while the eGFR remained stable with little variation from baseline. During the treatment period, there were minimal changes in serum potassium levels and serum creatinine levels and no treatment discontinuations or hospitalizations due to hyperkalemia were observed. Blood pressure decreased by about 10&#xa0;mmHg in 6 patients (30%), while there was no difference before and after the addition of finerenone in the remaining 14 (70%) patients.</p> Conclusion <p>The retrospective analysis indicates that finerenone treatment led to significant reductions in PCR and ACR in patients with membranous nephropathy over a 3 to 6-month period, with minimal impact on eGFR, SCr, and K+ levels, highlighting its capacity as a therapeutic option for MN patient group.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness and safety of finerenone in membranous nephropathy patients: a retrospective, real‑world study

  • 期刊论文

  • 发表日期：

    2025年1月21日

查看全文
  • Haowen Lin,
  • Qingqing Gao,
  • Yuhe Yin,
  • Siqi Peng,
  • Xiaoying Dong,
  • Zewen Zhao,
  • Renwei Huang,
  • Yiming Tao,
  • Sichun Wen,
  • Bohou Li,
  • Qiong Wu,
  • Sijia Li,
  • Ting Lin,
  • Hao Dai,
  • Feng Wen,
  • Zhuo Li,
  • Lixia Xu,
  • Jianchao Ma,
  • Zhonglin Feng,
  • Xiaoyan Bai,
  • Shuangxin Liu

摘要

Purpose

We aimed to conduct a retrospective analysis to assess the efficacy and safety of finerenone in patients with membranous nephropathy (MN).

Methods

This study conducted a retrospective analysis of patients with MN who were treated with finerenone for follow-up period ranging from 3 to 6 months. The study compared the estimated glomerular filtration rate (eGFR), urine total protein-to-creatinine ratio (PCR), urine albumin-to-creatinine ratio (ACR), serum creatinine concentration (SCr), blood pressure and serum potassium (K+) during the follow-up period.

Result

In this study, 20 patients with MN were treated with finerenone for a follow-up period of 3 to 6 months. Prior to treatment, the average eGFR was 65.15 mL/min/1.73 m2, the average PCR was 3643.63 mg/g, and the average ACR was 2489.44 mg/g. After 3 months of treatment, 80% of patients experienced a decrease in PCR. The median decrease percentages in PCR and ACR are 24.49% and 28.82%, respectively. After 6 months of treatment, the median decrease percentages in PCR and ACR are 42.03% and 43.66%, respectively while the eGFR remained stable with little variation from baseline. During the treatment period, there were minimal changes in serum potassium levels and serum creatinine levels and no treatment discontinuations or hospitalizations due to hyperkalemia were observed. Blood pressure decreased by about 10 mmHg in 6 patients (30%), while there was no difference before and after the addition of finerenone in the remaining 14 (70%) patients.

Conclusion

The retrospective analysis indicates that finerenone treatment led to significant reductions in PCR and ACR in patients with membranous nephropathy over a 3 to 6-month period, with minimal impact on eGFR, SCr, and K+ levels, highlighting its capacity as a therapeutic option for MN patient group.